AUTHOR=Wang Liu , Tian Yan-Fen , Deng Wen-Qing 

TITLE=Effects of metformin on acute respiratory distress syndrome in preclinical studies: a systematic review and meta-analysis

JOURNAL=Frontiers in Pharmacology

VOLUME=14

YEAR=2023

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1215307

DOI=10.3389/fphar.2023.1215307

ISSN=1663-9812

ABSTRACT=<p><bold>Introduction:</bold> In this study, we conducted a systematic review and meta-analysis to judge the effects of metformin on acute respiratory distress syndrome (ARDS) in a comprehensive and quantitative manner.</p><p><bold>Methods:</bold> We included studies that tested the effects of metformin on ALI or ARDS in <italic>in vivo</italic> studies. We excluded literature from which data could not be extracted or obtained. Electronic search was conducted to retrieve relevant literature from public databases, including PubMed, Web of Science, Embase, Scopus, and the Cochrane Central Register of Controlled Trials (inception to July 2023). Moreover, ProQuest Dissertations and Theses Global, Google Scholar, and Baidu scholar were inquired. Retrieved literature was screened and evaluated by pairs of reviewers independently according to pre-stated criteria. The Systematic Review Center for Laboratory Animal Experimentation risk of bias tool was used to evaluate the methodological quality of eligible literature. No restriction was exerted on publication status or language.</p><p><bold>Results:</bold> Fifteen preclinical studies were analyzed in this meta-analysis. Pooled results showed metformin effectively decreased pulmonary wet-to-dry weight ratios [SMD = −2.67 (−3.53 to −1.81), I<sup>2</sup> = 56.6%], protein content [SMD = −3.74 (−6.76 to −0.72), I<sup>2</sup> = 86.7%] and neutrophils [SMD = −3.47 (−4.69 to −2.26), I<sup>2</sup> = 0%] in BALF, pulmonary malondialdehyde [SMD = −1.98 (−3.77 to −0.20), I<sup>2</sup> = 74.2%] and myeloperoxidase activity [SMD = −3.15 (−4.79 to −1.52), I<sup>2</sup> = 74.5%], lung injury scores [SMD = −4.19 (−5.65 to −2.74), I<sup>2</sup> = 69.1%], and mortality at 24 h [RR = 0.43 (0.24–0.76), I<sup>2</sup> = 0%] as well as 48 and 72 h.</p><p><bold>Conclusion:</bold> Metformin inhibited pulmonary inflammation and oxidative stress and improved experimental lung injury and survival rates in animal models of ARDS. Results from randomized controlled trials are needed.</p>